Charité University, Berlin, Germany Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Berlin Germany (1710)

Organization Overview

First Clinical Trial
2020
NCT04227522
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Charité-Universitätsmedizin Berlin | Charité-Universitätsmedizin Berlin Campus Virchow-Klinikum | Charité University, Berlin, Germany | Klinik für Dermatologie, Charité-Universitätsmedizin, Berlin | Labor Berlin-Charité Vivantes G.m.b.H

Active Ingredients

Drugs in Phase 4 Trials (2)

bisoprolol (zebeta) (1 trial)

diltiazem (cardizem) (1 trial)

Drugs in Phase 3 Trials (2)

rivaroxaban (xarelto) (1 trial)

rucaparib (rubraca) (1 trial)

Drugs in Phase 2 Trials (3)

benralizumab (fasenra) (1 trial)

cenicriviroc (1 trial)

daratumumab (darzalex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma, Clear Cell (Phase 3)

Adenomyoepithelioma (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7